Ariel Esteban Bardach, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Argentina | 25 | 2024 | 232 | 2.900 |
Why?
|
| Latin America | 36 | 2024 | 379 | 2.750 |
Why?
|
| Health Care Costs | 13 | 2023 | 3207 | 2.430 |
Why?
|
| Cost of Illness | 17 | 2023 | 1859 | 2.150 |
Why?
|
| Taxes | 8 | 2023 | 221 | 1.850 |
Why?
|
| Caribbean Region | 18 | 2023 | 194 | 1.220 |
Why?
|
| Smoking | 13 | 2024 | 8984 | 1.140 |
Why?
|
| Herpes Zoster | 2 | 2021 | 264 | 1.030 |
Why?
|
| Mosquito Control | 3 | 2019 | 104 | 0.950 |
Why?
|
| Aedes | 3 | 2019 | 99 | 0.950 |
Why?
|
| Commerce | 6 | 2023 | 592 | 0.850 |
Why?
|
| Health Education | 2 | 2019 | 1056 | 0.810 |
Why?
|
| Chile | 7 | 2023 | 237 | 0.800 |
Why?
|
| Markov Chains | 3 | 2020 | 968 | 0.730 |
Why?
|
| Condylomata Acuminata | 2 | 2017 | 82 | 0.700 |
Why?
|
| Brazil | 8 | 2023 | 1264 | 0.700 |
Why?
|
| Mexico | 7 | 2024 | 689 | 0.690 |
Why?
|
| Colombia | 5 | 2021 | 258 | 0.690 |
Why?
|
| Alcohol Drinking | 4 | 2022 | 3965 | 0.680 |
Why?
|
| Streptococcus pneumoniae | 4 | 2024 | 714 | 0.660 |
Why?
|
| Workplace | 2 | 2022 | 836 | 0.660 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2021 | 2018 | 0.640 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2023 | 3338 | 0.640 |
Why?
|
| Public Policy | 2 | 2023 | 572 | 0.630 |
Why?
|
| Social Work | 1 | 2019 | 162 | 0.620 |
Why?
|
| Carbon Dioxide | 1 | 2022 | 1150 | 0.610 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 351 | 0.600 |
Why?
|
| Insecticides | 1 | 2019 | 195 | 0.600 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2018 | 116 | 0.590 |
Why?
|
| Health Promotion | 3 | 2019 | 2205 | 0.590 |
Why?
|
| Alcohol-Related Disorders | 1 | 2019 | 234 | 0.590 |
Why?
|
| Gene Amplification | 1 | 2021 | 1063 | 0.580 |
Why?
|
| Health Resources | 2 | 2020 | 912 | 0.550 |
Why?
|
| Evidence-Based Practice | 1 | 2020 | 500 | 0.550 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2017 | 127 | 0.550 |
Why?
|
| Shock, Septic | 1 | 2022 | 775 | 0.520 |
Why?
|
| Cost-Benefit Analysis | 8 | 2021 | 5388 | 0.510 |
Why?
|
| Cardiovascular Diseases | 11 | 2023 | 15142 | 0.500 |
Why?
|
| Quality-Adjusted Life Years | 8 | 2022 | 1683 | 0.490 |
Why?
|
| Epidemiologic Research Design | 1 | 2017 | 367 | 0.470 |
Why?
|
| Models, Theoretical | 8 | 2020 | 3587 | 0.460 |
Why?
|
| Humans | 101 | 2024 | 743811 | 0.450 |
Why?
|
| Primary Prevention | 2 | 2018 | 1167 | 0.430 |
Why?
|
| Cleavage Stage, Ovum | 1 | 2012 | 44 | 0.430 |
Why?
|
| Product Packaging | 2 | 2023 | 23 | 0.430 |
Why?
|
| Arsenic | 1 | 2015 | 328 | 0.420 |
Why?
|
| Peru | 4 | 2021 | 882 | 0.410 |
Why?
|
| Chickenpox | 1 | 2012 | 131 | 0.410 |
Why?
|
| Databases, Factual | 5 | 2023 | 7729 | 0.410 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 6773 | 0.410 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2014 | 139 | 0.400 |
Why?
|
| Herpesvirus 3, Human | 1 | 2012 | 204 | 0.400 |
Why?
|
| Receptor, erbB-2 | 1 | 2021 | 2418 | 0.400 |
Why?
|
| Product Labeling | 2 | 2023 | 79 | 0.400 |
Why?
|
| Prevalence | 13 | 2022 | 15211 | 0.390 |
Why?
|
| Quality of Life | 8 | 2021 | 12788 | 0.390 |
Why?
|
| Preoperative Care | 1 | 2020 | 2251 | 0.390 |
Why?
|
| Income | 2 | 2017 | 1913 | 0.380 |
Why?
|
| Papillomavirus Vaccines | 1 | 2017 | 491 | 0.370 |
Why?
|
| Private Sector | 2 | 2024 | 393 | 0.370 |
Why?
|
| Otitis Media | 2 | 2016 | 277 | 0.360 |
Why?
|
| Nigeria | 2 | 2023 | 733 | 0.350 |
Why?
|
| Papillomavirus Infections | 3 | 2017 | 1587 | 0.350 |
Why?
|
| Chagas Disease | 2 | 2022 | 166 | 0.350 |
Why?
|
| Models, Economic | 3 | 2020 | 712 | 0.350 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2014 | 329 | 0.340 |
Why?
|
| Hepatitis C | 1 | 2019 | 1591 | 0.340 |
Why?
|
| Blastocyst | 1 | 2012 | 424 | 0.340 |
Why?
|
| Pneumococcal Infections | 3 | 2024 | 497 | 0.340 |
Why?
|
| Venezuela | 2 | 2019 | 73 | 0.330 |
Why?
|
| Embryo Transfer | 1 | 2012 | 510 | 0.320 |
Why?
|
| Uruguay | 2 | 2019 | 104 | 0.320 |
Why?
|
| Students | 1 | 2018 | 1647 | 0.320 |
Why?
|
| Insulin | 1 | 2023 | 6584 | 0.320 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2024 | 3524 | 0.310 |
Why?
|
| Vaccines, Conjugate | 3 | 2024 | 333 | 0.310 |
Why?
|
| Colitis, Ulcerative | 1 | 2020 | 1911 | 0.300 |
Why?
|
| Health Facilities | 1 | 2012 | 572 | 0.300 |
Why?
|
| Crohn Disease | 1 | 2020 | 2304 | 0.290 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 1968 | 0.280 |
Why?
|
| Environmental Pollutants | 1 | 2015 | 1179 | 0.280 |
Why?
|
| Dengue | 2 | 2019 | 256 | 0.270 |
Why?
|
| Pneumococcal Vaccines | 3 | 2024 | 391 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 8430 | 0.260 |
Why?
|
| Beverages | 4 | 2023 | 820 | 0.260 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2020 | 3712 | 0.250 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2023 | 11729 | 0.250 |
Why?
|
| Bolivia | 2 | 2021 | 19 | 0.240 |
Why?
|
| Trypanosoma cruzi | 2 | 2022 | 197 | 0.230 |
Why?
|
| Female | 38 | 2024 | 380020 | 0.230 |
Why?
|
| Vaccines | 2 | 2023 | 823 | 0.220 |
Why?
|
| Social Security | 1 | 2023 | 101 | 0.220 |
Why?
|
| Neuroendoscopy | 1 | 2023 | 105 | 0.210 |
Why?
|
| Biomedical Research | 2 | 2017 | 3308 | 0.210 |
Why?
|
| Environmental Exposure | 2 | 2020 | 4232 | 0.210 |
Why?
|
| Pediatrics | 1 | 2017 | 3474 | 0.210 |
Why?
|
| Adult | 25 | 2023 | 213889 | 0.210 |
Why?
|
| Pandemics | 4 | 2023 | 8385 | 0.210 |
Why?
|
| Incidence | 9 | 2016 | 20948 | 0.200 |
Why?
|
| Occult Blood | 1 | 2022 | 176 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2022 | 9944 | 0.200 |
Why?
|
| Uterine Balloon Tamponade | 1 | 2021 | 42 | 0.190 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 13691 | 0.190 |
Why?
|
| Hemostatic Techniques | 1 | 2021 | 116 | 0.180 |
Why?
|
| Policy | 2 | 2021 | 508 | 0.180 |
Why?
|
| Chronic Disease | 1 | 2015 | 9139 | 0.180 |
Why?
|
| Costs and Cost Analysis | 2 | 2023 | 1680 | 0.180 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 2019 | 24 | 0.180 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2019 | 28 | 0.180 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2023 | 435 | 0.180 |
Why?
|
| Nitroimidazoles | 1 | 2020 | 106 | 0.170 |
Why?
|
| Cardiomyopathies | 2 | 2022 | 1911 | 0.170 |
Why?
|
| Food, Fortified | 1 | 2021 | 191 | 0.170 |
Why?
|
| Neoplasms | 5 | 2023 | 21675 | 0.170 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2023 | 397 | 0.170 |
Why?
|
| Coronary Artery Disease | 2 | 2017 | 6485 | 0.170 |
Why?
|
| Male | 24 | 2024 | 349776 | 0.170 |
Why?
|
| Paraguay | 1 | 2018 | 8 | 0.170 |
Why?
|
| Gonorrhea | 1 | 2023 | 335 | 0.170 |
Why?
|
| Publishing | 2 | 2019 | 833 | 0.170 |
Why?
|
| Poliomyelitis | 1 | 2019 | 103 | 0.160 |
Why?
|
| Sex Distribution | 2 | 2016 | 2298 | 0.160 |
Why?
|
| Overweight | 4 | 2023 | 2371 | 0.160 |
Why?
|
| Calcium, Dietary | 1 | 2021 | 525 | 0.160 |
Why?
|
| Child | 13 | 2024 | 77637 | 0.150 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 3089 | 0.150 |
Why?
|
| Postpartum Hemorrhage | 1 | 2021 | 258 | 0.150 |
Why?
|
| Neurosurgery | 1 | 2023 | 643 | 0.150 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2021 | 459 | 0.150 |
Why?
|
| Coronavirus | 1 | 2020 | 158 | 0.150 |
Why?
|
| Stroke | 2 | 2017 | 9975 | 0.150 |
Why?
|
| Antigua and Barbuda | 1 | 2016 | 1 | 0.150 |
Why?
|
| Pregnancy Outcome | 2 | 2021 | 2794 | 0.150 |
Why?
|
| Cuba | 1 | 2016 | 47 | 0.140 |
Why?
|
| Ozone | 1 | 2020 | 469 | 0.140 |
Why?
|
| Patient Care | 1 | 2023 | 638 | 0.140 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 687 | 0.140 |
Why?
|
| Jamaica | 1 | 2016 | 51 | 0.140 |
Why?
|
| Lactic Acid | 1 | 2022 | 1131 | 0.140 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2021 | 430 | 0.140 |
Why?
|
| Influenza, Human | 2 | 2021 | 1480 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 847 | 0.140 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2016 | 71 | 0.140 |
Why?
|
| Vaccination | 5 | 2023 | 3275 | 0.140 |
Why?
|
| Preventive Medicine | 1 | 2018 | 263 | 0.140 |
Why?
|
| Pregnancy | 9 | 2024 | 29140 | 0.130 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 971 | 0.130 |
Why?
|
| Adolescent | 8 | 2023 | 85729 | 0.130 |
Why?
|
| Periodicals as Topic | 2 | 2019 | 1429 | 0.130 |
Why?
|
| Mortality | 3 | 2016 | 2862 | 0.130 |
Why?
|
| Risk Factors | 11 | 2022 | 72252 | 0.130 |
Why?
|
| National Health Programs | 2 | 2016 | 445 | 0.130 |
Why?
|
| Neuralgia | 1 | 2021 | 570 | 0.130 |
Why?
|
| Protein C | 1 | 2015 | 138 | 0.120 |
Why?
|
| Ecosystem | 1 | 2019 | 473 | 0.120 |
Why?
|
| Meningitis, Pneumococcal | 1 | 2014 | 42 | 0.120 |
Why?
|
| Middle Aged | 15 | 2020 | 213241 | 0.120 |
Why?
|
| Survival Analysis | 4 | 2022 | 10251 | 0.120 |
Why?
|
| Delivery, Obstetric | 1 | 2021 | 906 | 0.120 |
Why?
|
| Aged | 13 | 2021 | 163178 | 0.120 |
Why?
|
| Cost Savings | 1 | 2019 | 925 | 0.120 |
Why?
|
| Influenza Vaccines | 1 | 2021 | 738 | 0.120 |
Why?
|
| Morbidity | 2 | 2019 | 1768 | 0.120 |
Why?
|
| Siblings | 1 | 2018 | 853 | 0.120 |
Why?
|
| Health Policy | 3 | 2020 | 2662 | 0.120 |
Why?
|
| Community Health Services | 1 | 2018 | 650 | 0.110 |
Why?
|
| Infertility | 1 | 2019 | 655 | 0.110 |
Why?
|
| Remission Induction | 1 | 2018 | 2384 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2019 | 1529 | 0.110 |
Why?
|
| Heart Failure | 1 | 2016 | 10896 | 0.110 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2024 | 1030 | 0.100 |
Why?
|
| Length of Stay | 2 | 2016 | 6311 | 0.100 |
Why?
|
| Drug Costs | 1 | 2019 | 1105 | 0.100 |
Why?
|
| Pregnancy, Multiple | 1 | 2012 | 217 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 7172 | 0.100 |
Why?
|
| Caregivers | 1 | 2023 | 2098 | 0.100 |
Why?
|
| Human papillomavirus 18 | 1 | 2011 | 128 | 0.090 |
Why?
|
| Age Factors | 3 | 2018 | 18355 | 0.090 |
Why?
|
| Hospitalization | 3 | 2021 | 10259 | 0.090 |
Why?
|
| Disability Evaluation | 1 | 2018 | 1828 | 0.090 |
Why?
|
| Oxygen | 1 | 2022 | 4189 | 0.090 |
Why?
|
| Computer Simulation | 3 | 2020 | 6188 | 0.090 |
Why?
|
| Aorta | 1 | 2018 | 2062 | 0.090 |
Why?
|
| Genital Neoplasms, Female | 1 | 2015 | 523 | 0.090 |
Why?
|
| Rotavirus Infections | 1 | 2011 | 86 | 0.090 |
Why?
|
| Rotavirus | 1 | 2011 | 109 | 0.090 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2019 | 1344 | 0.090 |
Why?
|
| Human papillomavirus 16 | 1 | 2011 | 261 | 0.090 |
Why?
|
| Adolescent Behavior | 1 | 2018 | 1151 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2022 | 9848 | 0.090 |
Why?
|
| Pregnancy Rate | 1 | 2012 | 643 | 0.080 |
Why?
|
| Program Evaluation | 1 | 2018 | 2483 | 0.080 |
Why?
|
| Critical Illness | 1 | 2022 | 2670 | 0.080 |
Why?
|
| Pneumonia, Bacterial | 1 | 2011 | 316 | 0.080 |
Why?
|
| Live Birth | 1 | 2012 | 512 | 0.080 |
Why?
|
| Life Expectancy | 1 | 2015 | 1184 | 0.080 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2018 | 1187 | 0.080 |
Why?
|
| Child, Preschool | 6 | 2024 | 40964 | 0.080 |
Why?
|
| Research Support as Topic | 1 | 2013 | 705 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2023 | 6259 | 0.080 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 57744 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2018 | 6457 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2019 | 2614 | 0.080 |
Why?
|
| Treatment Outcome | 7 | 2022 | 63042 | 0.080 |
Why?
|
| Research Design | 2 | 2022 | 5983 | 0.080 |
Why?
|
| Health Expenditures | 2 | 2021 | 2348 | 0.080 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 25032 | 0.080 |
Why?
|
| Public Health | 1 | 2021 | 2603 | 0.080 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2011 | 387 | 0.080 |
Why?
|
| Bronchiolitis | 1 | 2014 | 458 | 0.080 |
Why?
|
| Community-Acquired Infections | 1 | 2011 | 465 | 0.080 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 6895 | 0.080 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 4848 | 0.080 |
Why?
|
| Calcium | 1 | 2021 | 5755 | 0.080 |
Why?
|
| Bacteremia | 1 | 2014 | 963 | 0.080 |
Why?
|
| Mothers | 1 | 2018 | 2166 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2023 | 40545 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2023 | 4437 | 0.070 |
Why?
|
| Infant, Newborn | 5 | 2024 | 25609 | 0.070 |
Why?
|
| Research Report | 2 | 2021 | 355 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2019 | 2984 | 0.070 |
Why?
|
| Emigration and Immigration | 1 | 2010 | 402 | 0.070 |
Why?
|
| Air Pollution | 1 | 2020 | 2286 | 0.070 |
Why?
|
| Time Factors | 5 | 2023 | 40038 | 0.070 |
Why?
|
| Dietary Supplements | 1 | 2019 | 3292 | 0.070 |
Why?
|
| Mass Screening | 1 | 2022 | 5251 | 0.070 |
Why?
|
| Air Pollutants | 1 | 2020 | 2816 | 0.070 |
Why?
|
| Preventive Health Services | 1 | 2011 | 575 | 0.070 |
Why?
|
| Apolipoproteins E | 1 | 2011 | 1436 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2011 | 970 | 0.070 |
Why?
|
| Tobacco Use Disorder | 1 | 2011 | 688 | 0.070 |
Why?
|
| Age Distribution | 1 | 2011 | 2899 | 0.060 |
Why?
|
| Infant | 5 | 2024 | 35122 | 0.060 |
Why?
|
| Recurrence | 2 | 2019 | 8337 | 0.060 |
Why?
|
| Endovascular Procedures | 1 | 2018 | 1980 | 0.060 |
Why?
|
| Cefotaxime | 1 | 2024 | 35 | 0.060 |
Why?
|
| Waiting Lists | 1 | 2008 | 692 | 0.060 |
Why?
|
| Sex Factors | 1 | 2018 | 10394 | 0.060 |
Why?
|
| Obesity | 2 | 2023 | 12744 | 0.060 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 1125 | 0.060 |
Why?
|
| Classification | 1 | 2024 | 129 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 20827 | 0.060 |
Why?
|
| Stroke Volume | 1 | 2016 | 5002 | 0.060 |
Why?
|
| Ceftriaxone | 1 | 2024 | 168 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 11524 | 0.060 |
Why?
|
| Food Industry | 1 | 2023 | 68 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2016 | 5316 | 0.050 |
Why?
|
| Aluminum | 1 | 2023 | 152 | 0.050 |
Why?
|
| Patient Readmission | 1 | 2016 | 3117 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2023 | 77410 | 0.050 |
Why?
|
| Gram-Negative Bacteria | 1 | 2023 | 271 | 0.050 |
Why?
|
| Azithromycin | 1 | 2023 | 196 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3134 | 0.050 |
Why?
|
| Uterine Artery | 1 | 2021 | 36 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3241 | 0.050 |
Why?
|
| Vaccines, Subunit | 1 | 2022 | 168 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 2020 | 11708 | 0.050 |
Why?
|
| Vaccines, Inactivated | 1 | 2022 | 184 | 0.050 |
Why?
|
| Penicillins | 1 | 2024 | 380 | 0.050 |
Why?
|
| Nifurtimox | 1 | 2020 | 13 | 0.050 |
Why?
|
| Uterine Artery Embolization | 1 | 2021 | 62 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2019 | 23327 | 0.050 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2023 | 238 | 0.050 |
Why?
|
| Acute Disease | 1 | 2011 | 7150 | 0.050 |
Why?
|
| Ligation | 1 | 2021 | 452 | 0.050 |
Why?
|
| Qualitative Research | 2 | 2019 | 2682 | 0.050 |
Why?
|
| Economics | 1 | 2021 | 146 | 0.050 |
Why?
|
| Societies, Scientific | 1 | 2021 | 220 | 0.040 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2011 | 1518 | 0.040 |
Why?
|
| PubMed | 1 | 2019 | 121 | 0.040 |
Why?
|
| Poliovirus | 1 | 2019 | 109 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 15526 | 0.040 |
Why?
|
| Smoking Cessation | 1 | 2011 | 2071 | 0.040 |
Why?
|
| Cause of Death | 2 | 2020 | 3580 | 0.040 |
Why?
|
| Maternal Mortality | 1 | 2021 | 310 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 2019 | 221 | 0.040 |
Why?
|
| Tobacco Industry | 1 | 2019 | 126 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 552 | 0.040 |
Why?
|
| Journal Impact Factor | 1 | 2019 | 155 | 0.040 |
Why?
|
| Spain | 2 | 2010 | 464 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2023 | 1340 | 0.040 |
Why?
|
| Americas | 1 | 2017 | 110 | 0.040 |
Why?
|
| Asia, Southeastern | 1 | 2017 | 111 | 0.040 |
Why?
|
| Animals | 5 | 2023 | 168660 | 0.040 |
Why?
|
| Efficiency | 1 | 2021 | 462 | 0.040 |
Why?
|
| Nitrogen Dioxide | 1 | 2020 | 490 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2023 | 999 | 0.040 |
Why?
|
| Prognosis | 1 | 2018 | 29052 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2023 | 1870 | 0.040 |
Why?
|
| Students, Medical | 1 | 2010 | 1862 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2021 | 775 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 39001 | 0.040 |
Why?
|
| Immunity, Mucosal | 1 | 2019 | 490 | 0.030 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2019 | 469 | 0.030 |
Why?
|
| Registries | 1 | 2012 | 8090 | 0.030 |
Why?
|
| Vagina | 1 | 2021 | 825 | 0.030 |
Why?
|
| Atherosclerosis | 1 | 2011 | 3445 | 0.030 |
Why?
|
| Gross Domestic Product | 1 | 2015 | 77 | 0.030 |
Why?
|
| Fetus | 1 | 2023 | 1880 | 0.030 |
Why?
|
| Hysterectomy | 1 | 2021 | 927 | 0.030 |
Why?
|
| Ethanol | 1 | 2022 | 1343 | 0.030 |
Why?
|
| Public Opinion | 1 | 2019 | 477 | 0.030 |
Why?
|
| Triazoles | 1 | 2020 | 904 | 0.030 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2021 | 1320 | 0.030 |
Why?
|
| Epidemiology | 1 | 2016 | 287 | 0.030 |
Why?
|
| Young Adult | 4 | 2012 | 56392 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2019 | 711 | 0.030 |
Why?
|
| Neurosurgical Procedures | 1 | 2023 | 2002 | 0.030 |
Why?
|
| Hip Fractures | 1 | 2021 | 955 | 0.030 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 5319 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 685 | 0.030 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2011 | 43 | 0.030 |
Why?
|
| Databases, Bibliographic | 1 | 2012 | 128 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2021 | 1580 | 0.030 |
Why?
|
| Data Collection | 1 | 2021 | 3339 | 0.020 |
Why?
|
| Haemophilus influenzae | 1 | 2011 | 172 | 0.020 |
Why?
|
| Pneumonia | 1 | 2023 | 2133 | 0.020 |
Why?
|
| Europe | 1 | 2017 | 3336 | 0.020 |
Why?
|
| Disease | 1 | 2016 | 680 | 0.020 |
Why?
|
| Survivors | 1 | 2021 | 2291 | 0.020 |
Why?
|
| Rotavirus Vaccines | 1 | 2011 | 61 | 0.020 |
Why?
|
| Decision Making | 1 | 2023 | 3887 | 0.020 |
Why?
|
| Geography | 1 | 2011 | 669 | 0.020 |
Why?
|
| Premature Birth | 1 | 2021 | 1722 | 0.020 |
Why?
|
| Gastroenteritis | 1 | 2011 | 245 | 0.020 |
Why?
|
| Particulate Matter | 1 | 2020 | 2529 | 0.020 |
Why?
|
| Social Class | 1 | 2017 | 1997 | 0.020 |
Why?
|
| Developing Countries | 1 | 2021 | 2815 | 0.020 |
Why?
|
| Bone Density | 1 | 2021 | 3460 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2011 | 651 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 19894 | 0.020 |
Why?
|
| Genotype | 2 | 2011 | 12944 | 0.020 |
Why?
|
| Poverty | 1 | 2017 | 2660 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 2971 | 0.020 |
Why?
|
| Health Personnel | 1 | 2019 | 3217 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 3585 | 0.020 |
Why?
|
| Triglycerides | 1 | 2011 | 2453 | 0.010 |
Why?
|
| Health Services Research | 1 | 2011 | 1836 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 2010 | 1151 | 0.010 |
Why?
|
| Cholesterol | 1 | 2011 | 2922 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2011 | 6356 | 0.010 |
Why?
|
| Disease Outbreaks | 1 | 2011 | 1771 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2010 | 1373 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 2011 | 1956 | 0.010 |
Why?
|
| Health Surveys | 1 | 2011 | 4036 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2011 | 1887 | 0.010 |
Why?
|
| Alleles | 1 | 2011 | 6934 | 0.010 |
Why?
|
| Urban Population | 1 | 2008 | 2021 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 14714 | 0.010 |
Why?
|
| Life Style | 1 | 2010 | 3833 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 21733 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 15518 | 0.010 |
Why?
|
| Diet | 1 | 2010 | 7930 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 17439 | 0.010 |
Why?
|
| Hypertension | 1 | 2010 | 8480 | 0.010 |
Why?
|